Latest Transformation News

Following a critical ASIC Inquiry Interim Report, ASX has pledged a strategic reset including a $150 million capital charge and enhanced board independence to restore market confidence.

4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.

Echelon Resources has signed a term sheet with the Northern Territory’s Power and Water Corporation to supply gas through 2034, including plans for four new wells that could significantly increase output from the Amadeus Basin.

Radiopharm Theranostics reports promising interim Phase 2b results for RAD 101, achieving 92% concordance with MRI in detecting brain metastases, paving the way for a pivotal study in 2026.

Dart Mining has reported its highest gold assay results to date from the Banshee antimony-gold mine in Queensland, revealing promising mineralisation that could signal a significant gold-rich system. The ongoing drilling program and forthcoming assays are set to further define the project's potential.

Ballymore Resources has reported compelling high-grade silver-lead-zinc-indium mineralisation from recent drilling at its Torpy’s and Little Torpy’s prospects in north Queensland, highlighting the potential for a significant shallow polymetallic deposit.

Genetic Signatures announces the upcoming departure of CEO Allison Rossiter, initiating a leadership transition as the company intensifies its focus on US market expansion.

IperionX partners with Carver Pump to fast-track production of critical titanium components for U.S. Navy ships, aiming to cut lead times from over a year to under a week.

Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.

Fortifai Limited introduces Nol8, a breakthrough platform that processes data in real time with millisecond latency, promising to transform industries reliant on massive data flows.

Fortifai Limited has acquired an exclusive license to Nol8, a breakthrough real-time data processing technology developed by the Technion. This acquisition positions Fortifai to revolutionize data handling across gaming, AI, finance, and cybersecurity sectors.

Dimerix has successfully completed recruitment and dosing of 286 adult patients in its Phase 3 ACTION3 trial evaluating DMX-200 for focal segmental glomerulosclerosis (FSGS), advancing toward regulatory discussions with the FDA.